Peptipedia
CognitivePreclinicalAnimal Studies

PE-22-28

Also known as PE22-28, Spadin Analog, TREK-1 Inhibitor Peptide

A synthetic heptapeptide (7 amino acids) derived from Spadin, a naturally occurring antidepressant peptide, with enhanced stability.

Preclinical - Animal studies only
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

100-300 mcg intranasal or subcutaneous

Frequency

Once daily

Duration

Research protocols vary, often 2-4 weeks

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 100-300 mcg intranasal or subcutaneous via Intranasal or subcutaneous injection, Once daily. Dose range: 100-300 mcg per dose. Duration: Research protocols vary, often 2-4 weeks.

Timing & Administration

Administer via Intranasal or subcutaneous injection. Frequency: Once daily.

Mechanism of Action

Selectively blocks TREK-1 (TWIK-related potassium channel 1), a two-pore domain potassium channel highly expressed in the brain, to increase neuronal activity and neurotransmitter enhancement.

Research Summary

Evidence level: animal studies. Clinical status: Preclinical - Animal studies only.

Side Effects & Safety

Important Warnings

  • Not approved for human use
  • Unknown long-term effects.
Limited safety data (preclinical only)
potential headache
nasal irritation (intranasal)
theoretical cardiac TREK-1 channel effects

References

No references available.

Related Peptides

Browse all →
SelankCognitive

A synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects.

View profile
SemaxCognitive

Synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Used clinically in Russia for stroke, traumatic brain injury, and cognitive disorders.

View profile
CerebrolysinCognitive

A neuropeptide mixture derived from porcine brain tissue, indicated for neurological conditions including stroke recovery, cognitive decline, and traumatic brain injury.

View profile